Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 137-144

  Thürlimann, Beat ^a,b   Price, Karen N ^c   Gelber, Richard D ^c,d,e   Holmberg, Stig B ^f   Crivellari, Diana ^g   Colleoni, Marco ^h   Collins, John ⁱ   Forbes, John F ^j   Castiglione Gertsch, Monica ^k   Coates, Alan S ^l,m   Goldhirsch, Aron ^h,n  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k IBCSG Coordinating Center   (Switzerland)

^l International Breast Cancer Study Group   (Switzerland)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

Breast cancer; Estrogen receptor; Goserelin; Ovarian ablation; Ovarian function suppression; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; GONADORELIN DERIVATIVE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY FUNCTION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 58049196789     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9912-9     Document Type: Article

References (19)

1. RR Love J Philips 2002 Oophorectomy for breast cancer: history revisited J Natl Cancer Inst 94 1433 1434
2. Early Breast Cancer Trialists' Cooperative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
3. JGM Klijn RW Blamey R Boccardo for the Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer 2001 Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 343 353
4. A Goldhirsch WC Wood RD Gelber 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144
5. NE Davidson AM O'Neill AM Vukov 2005 Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188) J Clin Oncol 23 5973 5982
6. S Dellapasqua M Colleoni RD Gelber A Goldhirsch 2005 Adjuvant endocrine therapy for premenopausal women with early breast cancer J Clin Oncol 23 1736 1750
7. The [T1]Adjuvant Breast Cancer Trials Collaborative Group (2007) Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 99:516-525
8. International Breast Cancer Study Group 2001 Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93 Breast 10 Suppl 3 130 138
9. Early Breast Cancer Trialists' Collaborative Group 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1681 1692
10. International Breast Cancer Study Group 2006 Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93 J Clin Oncol 24 1332 1341
11. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481
12. Greenwood M (1926) The natural duration of cancer. HM Stationary Office, London
13. DR Cox 1972 Regression models and life-tables (with discussion) J R Stat Soc 34 187 220
14. NL Henry DF Hayes 2007 Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? J Clin Oncol 25 2501 2503
15. NG Leining S Gelber R Rosenberg 2006 Menopausal-type symptoms in young breast cancer survivors Ann Oncol 17 1777 1782
16. International Breast Cancer Study Group 2003 Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst 95 1833 1846
17. KN Price A Goldhirsch for the IBCSG 2005 Clinical trial update: international Breast Cancer Study Group Breast Cancer Res 7 252 254
18. National Cancer Institute. US National Institutes of Health. The TAILORx breast cancer trial. http://www.cancer.gov/clinicaltrials/digestpage/TAILORx
19. Breast International Group. MINDACT (microarray in node negative disease may avoid chemotherapy). http://www.breastinternationalgroup.org/TransBIG/ Mindact.aspx